Study identifies strategies to reduce breast cancer growth and related skeletal lesions
RI-MUHC team publishes findings in the journal, Bone Research
Early treatment trial of hydroxychloroquine shows no symptomatic benefit for COVID-19 patients
Adult outpatients with mild symptoms of COVID-19 don’t benefit from taking hydroxychloroquine
Sodium found to regulate the biological clock of mice
New study by RI-MUHC researchers first to establish that physiological signals influence circadian rhythms
At the heart of precision medicine
New translational collaboration aims to transform approach to heart muscle disease
Novel gene therapy trial offers hope to patients with rare metabolic disease
Samuel is the first Canadian and the ninth patient worldwide to participate in the second phase of a study using gene...
Call for Applications: Executive Director and Chief Scientific Officer, Research Institute of the McGill University Health Centre (RI-MUHC)
The RI-MUHC is seeking a dynamic and strategic leader to serve as its next Executive Director and Chief Scientific Officer (ED/CSO)
Interdisciplinary Consortium Receives Grant to Develop Next-Generation Cell-Based Cancer Vaccines
Cell-based cancer vaccines are revolutionizing the treatment of previously incurable cancers
COVID-19 pandemic: Looking back to better tackle future challenges
In two recent studies, RI-MUHC researchers provide useful information for evaluating public health strategies
Canadian researchers work together to develop made-in-Canada COVID-19 testing capacity
The road towards Canadian testing capacity began in Montreal
Rifampin for Latent TB: Shorter and safer than the standard treatment, but also cheaper
A new study shows that rifampin regimen is cheaper than isoniazid for latent tuberculosis